Phase 2
Systemic Sclerosis ILD
Intervention Type:
Oral Drug
Funder Type:
Organization | University

Drug Details

Ixazomib is a proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.

Study Purpose

The purpose of this research study is to learn about the effects of the medication ixazomib in participants with scleroderma/systemic sclerosis including its safety and tolerability, its effects on skin, lungs and other organs, and its effects on overall health and quality of life.

Find a Clinical Trial